Does the media prefer BCYC or KURA?

In the previous week, Kura Oncology had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 2 mentions for Kura Oncology and 1 mentions for Bicycle Therapeutics. Kura Oncology's average media sentiment score of 0.46 beat Bicycle Therapeutics' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, BCYC or ANL?

Adlai Nortye has lower revenue, but higher earnings than Bicycle Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bicycle Therapeutics $61.21M 4.12 -$218.96M -$2.73 N/A Adlai Nortye $18.06M 56.17 -$35.53M N/A N/A

Does the media refer more to BCYC or ANL?

In the previous week, Adlai Nortye had 2 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 3 mentions for Adlai Nortye and 1 mentions for Bicycle Therapeutics. Adlai Nortye's average media sentiment score of 0.92 beat Bicycle Therapeutics' score of 0.00 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adlai Nortye 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALMS or BCYC more profitable?

Bicycle Therapeutics has a net margin of -311.11% compared to Alumis' net margin of -5,933.46%. Bicycle Therapeutics' return on equity of -33.22% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -5,933.46% -93.15% -74.50% Bicycle Therapeutics -311.11% -33.22% -27.79%

Does the media refer more to ALMS or BCYC?

In the previous week, Alumis had 3 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 4 mentions for Alumis and 1 mentions for Bicycle Therapeutics. Alumis' average media sentiment score of 0.57 beat Bicycle Therapeutics' score of 0.00 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicycle Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BCYC or ABUS?

In the previous week, Bicycle Therapeutics and Bicycle Therapeutics both had 1 articles in the media. Arbutus Biopharma's average media sentiment score of 1.73 beat Bicycle Therapeutics' score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arbutus Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Bicycle Therapeutics (BCYC) Competitors

$3.60 -0.13 (-3.49%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.60 0.00 (-0.14%)

As of 09/23/2026 07:30 PM Eastern

Compare

BCYC vs. CVAC, KURA, ANL, ALMS, and ABUS

Should you buy Bicycle Therapeutics stock or one of its competitors? Bicycle Therapeutics's main competitors and comparable companies include CureVac (CVAC), Kura Oncology (KURA), Adlai Nortye (ANL), Alumis (ALMS), and Arbutus Biopharma (ABUS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Bicycle Therapeutics compare to CureVac?

Bicycle Therapeutics (NASDAQ:BCYC) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 22.0% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CureVac has a net margin of 199.92% compared to Bicycle Therapeutics' net margin of -311.11%. CureVac's return on equity of -23.03% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%
CureVac	199.92%	-23.03%	-19.09%

CureVac has higher revenue and earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$61.21M	4.12	-$218.96M	-$2.73	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

In the previous week, Bicycle Therapeutics had 1 more articles in the media than CureVac. MarketBeat recorded 1 mentions for Bicycle Therapeutics and 0 mentions for CureVac. Bicycle Therapeutics' average media sentiment score of 0.00 equaled CureVac'saverage media sentiment score.

Company	Overall Sentiment
Bicycle Therapeutics	Neutral
CureVac	Neutral

Bicycle Therapeutics currently has a consensus target price of $13.86, indicating a potential upside of 284.92%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Bicycle Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bicycle Therapeutics has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Summary

CureVac beats Bicycle Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Kura Oncology?

Bicycle Therapeutics (NASDAQ:BCYC) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Bicycle Therapeutics presently has a consensus price target of $13.86, indicating a potential upside of 284.92%. Kura Oncology has a consensus price target of $25.40, indicating a potential upside of 130.07%. Given Bicycle Therapeutics' higher probable upside, analysts clearly believe Bicycle Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Kura Oncology had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 2 mentions for Kura Oncology and 1 mentions for Bicycle Therapeutics. Kura Oncology's average media sentiment score of 0.46 beat Bicycle Therapeutics' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.2% of Bicycle Therapeutics shares are held by institutional investors. 22.0% of Bicycle Therapeutics shares are held by insiders. Comparatively, 7.6% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bicycle Therapeutics has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

Bicycle Therapeutics has a net margin of -311.11% compared to Kura Oncology's net margin of -384.30%. Bicycle Therapeutics' return on equity of -33.22% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%
Kura Oncology	-384.30%	-207.18%	-45.17%

Bicycle Therapeutics has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$61.21M	4.12	-$218.96M	-$2.73	N/A
Kura Oncology	$67.48M	14.55	-$278.67M	-$3.37	N/A

Summary

Bicycle Therapeutics beats Kura Oncology on 10 of the 16 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Adlai Nortye?

Bicycle Therapeutics (NASDAQ:BCYC) and Adlai Nortye (NASDAQ:ANL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Adlai Nortye has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. Adlai Nortye's return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%
Adlai Nortye	N/A	N/A	N/A

In the previous week, Adlai Nortye had 2 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 3 mentions for Adlai Nortye and 1 mentions for Bicycle Therapeutics. Adlai Nortye's average media sentiment score of 0.92 beat Bicycle Therapeutics' score of 0.00 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adlai Nortye	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adlai Nortye has lower revenue, but higher earnings than Bicycle Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$61.21M	4.12	-$218.96M	-$2.73	N/A
Adlai Nortye	$18.06M	56.17	-$35.53M	N/A	N/A

Bicycle Therapeutics currently has a consensus target price of $13.86, suggesting a potential upside of 284.92%. Adlai Nortye has a consensus target price of $29.50, suggesting a potential upside of 87.30%. Given Bicycle Therapeutics' higher probable upside, research analysts clearly believe Bicycle Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Bicycle Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 22.0% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Adlai Nortye beats Bicycle Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Alumis?

Alumis (NASDAQ:ALMS) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Alumis currently has a consensus target price of $33.27, suggesting a potential upside of 347.21%. Bicycle Therapeutics has a consensus target price of $13.86, suggesting a potential upside of 284.92%. Given Alumis' stronger consensus rating and higher probable upside, analysts clearly believe Alumis is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Alumis has a beta of -0.81, indicating that its share price is 181% less volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

86.2% of Bicycle Therapeutics shares are held by institutional investors. 33.7% of Alumis shares are held by company insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bicycle Therapeutics has a net margin of -311.11% compared to Alumis' net margin of -5,933.46%. Bicycle Therapeutics' return on equity of -33.22% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-5,933.46%	-93.15%	-74.50%
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%

In the previous week, Alumis had 3 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 4 mentions for Alumis and 1 mentions for Bicycle Therapeutics. Alumis' average media sentiment score of 0.57 beat Bicycle Therapeutics' score of 0.00 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicycle Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bicycle Therapeutics has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	40.04	-$243.32M	-$3.86	N/A
Bicycle Therapeutics	$61.21M	4.12	-$218.96M	-$2.73	N/A

Summary

Bicycle Therapeutics beats Alumis on 9 of the 17 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Arbutus Biopharma?

Bicycle Therapeutics (NASDAQ:BCYC) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Bicycle Therapeutics has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Arbutus Biopharma has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$61.21M	4.12	-$218.96M	-$2.73	N/A
Arbutus Biopharma	$14.08M	68.24	-$33.50M	$0.79	6.14

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 22.0% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bicycle Therapeutics presently has a consensus target price of $13.86, indicating a potential upside of 284.92%. Arbutus Biopharma has a consensus target price of $5.00, indicating a potential upside of 3.09%. Given Bicycle Therapeutics' higher probable upside, analysts clearly believe Bicycle Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Arbutus Biopharma has a net margin of 84.22% compared to Bicycle Therapeutics' net margin of -311.11%. Arbutus Biopharma's return on equity of 90.98% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%
Arbutus Biopharma	84.22%	90.98%	82.34%

In the previous week, Bicycle Therapeutics and Bicycle Therapeutics both had 1 articles in the media. Arbutus Biopharma's average media sentiment score of 1.73 beat Bicycle Therapeutics' score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Arbutus Biopharma beats Bicycle Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Bicycle Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCYC vs. The Competition

Export

Metric	Bicycle Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$261.07M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-1.32	13.88	274.02	25.69
Price / Sales	4.12	1,311.42	632.76	76.07
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.41	15.30	10.44	6.32
Net Income	-$218.96M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-2.17%	-1.71%	-0.66%	0.17%
1 Month Performance	-16.86%	-6.17%	-3.16%	-3.27%
1 Year Performance	-52.51%	30.64%	15.15%	5.58%

Bicycle Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
BCYC Bicycle Therapeutics	1.8836 of 5 stars	$3.60 -3.5%	$13.86 +284.9%	-49.2%	$261.07M	$61.21M	N/A	288
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
KURA Kura Oncology	3.3862 of 5 stars	$11.70 +0.9%	$25.40 +117.1%	+34.0%	$1.04B	$67.48M	N/A	260
ANL Adlai Nortye	2.5084 of 5 stars	$16.05 +3.1%	$29.50 +83.9%	+779.9%	$1.03B	$5M	N/A	109
ALMS Alumis	3.8196 of 5 stars	$7.86 -0.6%	$33.27 +323.6%	+81.5%	$1.02B	$24.05M	N/A	239

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCYC) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicycle Therapeutics (BCYC) Competitors

BCYC vs. CVAC, KURA, ANL, ALMS, and ABUS

How does Bicycle Therapeutics compare to CureVac?

Summary

How does Bicycle Therapeutics compare to Kura Oncology?

Summary

How does Bicycle Therapeutics compare to Adlai Nortye?

Summary

How does Bicycle Therapeutics compare to Alumis?

Summary

How does Bicycle Therapeutics compare to Arbutus Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC vs. The Competition

Bicycle Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicycle Therapeutics (BCYC) Competitors

BCYC vs. CVAC, KURA, ANL, ALMS, and ABUS

How does Bicycle Therapeutics compare to CureVac?

Do institutionals & insiders have more ownership in BCYC or CVAC?

Is BCYC or CVAC more profitable?

Which has preferable earnings & valuation, BCYC or CVAC?

Does the media prefer BCYC or CVAC?

Do analysts recommend BCYC or CVAC?

Which has more risk & volatility, BCYC or CVAC?

Summary

How does Bicycle Therapeutics compare to Kura Oncology?

Do analysts prefer BCYC or KURA?

Does the media prefer BCYC or KURA?

Do insiders & institutionals believe in BCYC or KURA?

Which has more volatility & risk, BCYC or KURA?

Is BCYC or KURA more profitable?

Which has higher earnings & valuation, BCYC or KURA?

Summary

How does Bicycle Therapeutics compare to Adlai Nortye?

Is BCYC or ANL more profitable?

Does the media refer more to BCYC or ANL?

Which has preferable earnings & valuation, BCYC or ANL?

Do analysts prefer BCYC or ANL?

Which has more risk and volatility, BCYC or ANL?

Do institutionals and insiders hold more shares of BCYC or ANL?

Summary

How does Bicycle Therapeutics compare to Alumis?

Do analysts rate ALMS or BCYC?

Which has more volatility & risk, ALMS or BCYC?

Do insiders & institutionals have more ownership in ALMS or BCYC?

Is ALMS or BCYC more profitable?

Does the media refer more to ALMS or BCYC?

Which has preferable earnings & valuation, ALMS or BCYC?

Summary

How does Bicycle Therapeutics compare to Arbutus Biopharma?

Which has more volatility and risk, BCYC or ABUS?

Which has better earnings and valuation, BCYC or ABUS?

Do insiders and institutionals believe in BCYC or ABUS?

Do analysts recommend BCYC or ABUS?

Is BCYC or ABUS more profitable?

Does the media refer more to BCYC or ABUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC vs. The Competition

Bicycle Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools